Long-term Safety Extension to Study TRCA-301

PHASE3CompletedINTERVENTIONAL
Enrollment

196

Participants

Timeline

Start Date

December 20, 2017

Primary Completion Date

February 22, 2019

Study Completion Date

February 22, 2019

Conditions
Metabolic Acidosis
Interventions
DRUG

TRC101

Oral suspension

DRUG

Placebo

Oral suspension

Trial Locations (29)

30342

Investigative Site 95, Atlanta

33015

Investigative Site 59, Hialeah

33024

Investigative Site 93, Hollywood

33313

Investigative Site 92, Lauderdale Lakes

78215

Investigative Site 52, San Antonio

85032

Investigative Site 55, Phoenix

90022

Investigative Site 91, Los Angeles

Unknown

Investigative Site 11, Sofia

Investigative Site 31, Tbilisi

Investigative Site 32, Tbilisi

Investigative Site 33, Tbilisi

Investigative Site 34, Tbilisi

Investigative Site 35, Tbilisi

Investigative Site 36, Tbilisi

Investigative Site 37, Tbilisi

Investigative Site 41, Budapest

Investigative Site 46, Budapest

Investigative Site 49, Hódmezővásárhely

Investigative Site 44, Kistarcsa

Investigative Site 61, Vršac

Investigative Site 72, Jesenice

Investigative Site 71, Maribor

Investigative Site 81, Kharkiv

Investigative Site 83, Kharkiv

Investigative Site 87, Kharkiv

Investigative Site 88, Kharkiv

Investigative Site 84, Kyiv

Investigative Site 85, Kyiv

Investigative Site 86, Kyiv

All Listed Sponsors
lead

Tricida, Inc.

INDUSTRY

NCT03390842 - Long-term Safety Extension to Study TRCA-301 | Biotech Hunter | Biotech Hunter